Immunome Inc. (IMNM) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Immunome Inc. (IMNM:NASDAQ), powered by AI.

Current Price
$17.91
P/E Ratio
-7.4
Market Cap
1.6B
Sector
Healthcare
What is the Immunome Inc. stock price forecast?

Immunome Inc. is currently trading at $17.91. View real-time AI analysis on Alpha Lenz.

What is Immunome Inc. insider trading activity?

View the latest insider trading data for Immunome Inc. on Alpha Lenz.

What is Immunome Inc.'s P/E ratio?

Immunome Inc.'s P/E ratio is -7.4.

Immunome Inc.

NASDAQ · IMNM
$17.91-0.16(-0.89%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Immunome Inc.'s future dividend policy...
Alpha Chat Insight

Immunome Inc. trades at a P/E of -7.4 (undervalued) with modest ROE of -52.1%.

Ask for details

Company Overview

Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector. The primary focus of the company is to advance immunotherapy-based cancer treatments through its proprietary discovery engine that harnesses the immune system's natural capabilities. Immunome’s approach involves leveraging its unique antigen technology to identify novel targets and develop therapeutic antibodies, aimed at enabling the body's immune response to recognize and combat cancer more effectively. This cutting-edge focus places Immunome Inc. squarely at the forefront of the biologics market, with potential applications spanning various oncology therapies. Since its inception, the company has continually explored partnerships with academic institutions and other biotech firms, enhancing collaborative efforts to propel novel findings from the laboratory to clinical trials. Immunome’s efforts contribute significantly to the pharmaceutical and healthcare industries, underscoring the growing importance of targeted therapies and personalized medicine in addressing complex medical challenges. Based in Exton, Pennsylvania, Immunome Inc. represents a key player in translating breakthrough immunological insights into tangible healthcare solutions, emphasizing robust scientific innovation in combating one of the world's most persistent health issues.

CEODr. Clay B. Siegall Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees155

Company Statistics

FY 2025

Profile

$1.56BMarket Cap
$6.94MRevenue
0.00Shares Out
155Employees

Margins

N/AGross
-3186.26%EBITDA
-3228.83%Operating
-3059.99%Pre-Tax
-3059.99%Net

Valuation

-7.37P/E
2.47P/B
225.39EV/Sales
-4.14EV/EBITDA
-7.56P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-46.00%ROA
-52.09%ROE
-48.54%ROIC

Financial Health

$653.48MCash & Cash Equivalents
$-604.64MNet Debt
7.70%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Immunome Inc. (ticker: IMNM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 155 employees. Market cap is $1.6B.

The current price is $17.91 with a P/E ratio of -7.37x and P/B of 2.47x.

ROE is -52.09% and operating margin is -3228.83%. Annual revenue is $7M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Immunome Inc. (IMNM) Stock Forecast 2026 $17.91 — Price, Financials & Analyst Targets | Alpha Lenz